PARTNER 3 Trial - Aortic Valve-in-Valve
A Prospective, Single-Arm, Multicenter Study to Investigate the Safety and Effectiveness of SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve Implantation in Patients With a Failing Aortic Bioprosthetic Valve
Sponsor: Edwards Lifesciences
Listed as NCT03003299, this NA trial focuses on Aortic Stenosis and Aortic Stenosis, Severe and remains actively recruiting participants. Sponsored by Edwards Lifesciences, it has been updated 17 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jun 2023 — Jun 2024 [monthly]
Recruiting NA
▶ Show 12 earlier versions
-
May 2022 — Jun 2023 [monthly]
Recruiting NA
-
Dec 2021 — May 2022 [monthly]
Recruiting NA
-
Jan 2021 — Dec 2021 [monthly]
Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Recruiting NA
-
Jan 2019 — Jan 2020 [monthly]
Recruiting NA
-
Dec 2018 — Jan 2019 [monthly]
Recruiting NA
-
Nov 2018 — Dec 2018 [monthly]
Recruiting NA
Phase: PHASE3 → NA
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Edwards Lifesciences
For direct contact, visit the study record on ClinicalTrials.gov .